1. 1
RedLANO e–Journal
2 0 1 2
www.redlano.org
( E p u b a h e a d o f p r i n t )
Ciencias básicas
Duncan, C. G. et. al. A heterozygous IDH1R132H/WT mutation
induces genome-wide alterations in DNA methylation. Geno-
me Res. 2012 Dec;22(12):2339-55.
Lu, C. et. al. IDH mutation impairs histone demethylation
and results in a block to cell differentiation. Nature. 2012 Feb
15;483(7390):474-8.
Sturm, D. et. al. Hotspot mutations in H3F3A and IDH1 define
distinct epigenetic and biological subgroups of glioblastoma.
Cancer Cell. 2012 Oct 16;22(4):425-37.
Turcan, S. et. al. IDH1 mutation is sufficient to establish the
glioma hypermethylator phenotype. Nature. 2012 Feb
15;483(7390):479-83.
Chen, J. et. al. A restricted cell population propagates glio-
blastoma growth after chemotherapy. Nature. 2012 Aug
23;488(7412):522-6.
Friedmann-Morvinski, D. et. al. Dedifferentiation of neurons
and astrocytes by oncogenes can induce gliomas in mice.
Science. 2012 Nov 23;338(6110):1080-4.
Muller, F. L. et. al. Passenger deletions generate therapeutic
vulnerabilities in cancer. Nature. 2012 Aug 16;488(7411):337-
42.
LECTURAS RECOMENDADAS NEURO–ONCOLOGÍA 2012
Sasaki, M. et. al. IDH1(R132H) mutation increases murine hae-
matopoietic progenitors and alters epigenetics. Nature. 2012
Aug 30;488(7413):656-9.
Singh, D. et. al. Transforming fusions of FGFR and TACC genes
in human glioblastoma. Science. 2012 Sep 7;337(6099):1231-5.
Snuderl, M. et. al. Mosaic amplification of multiple receptor
tyrosine kinase genes in glioblastoma. Cancer Cell. 2011 Dec
13;20(6):810-7.
Vivanco, I. et. al. Differential sensitivity of glioma- versus lung
cancer-specific EGFR mutations to EGFR kinase inhibitors.
Cancer Discov. 2012 May;2(5):458-71.
Koivunen, P. et. al. Transformation by the (R)-enantiomer of
2-hydroxyglutarate linked to EGLN activation. Nature. 2012
Feb 15;483(7390):484-8.
Neuro-oncología pediátrica
Jones, D. T. et. al. Dissecting the genomic complexi-
ty underlying medulloblastoma. Nature. 2012 Aug
2;488(7409):100-5.
Northcott, P. A. et. al. Subgroup-specific structural variation
across 1,000 medulloblastoma genomes. Nature. 2012 Aug
2;488(7409):49-56.

2. 2
RedLANO e–Journal
2 0 1 2
www.redlano.org
( E p u b a h e a d o f p r i n t )
Wu, G. et. al. Somatic histone H3 alterations in pediatric
diffuse intrinsic pontine gliomas and non-brainstem glio-
blastomas. Nat Genet. 2012 Jan 29;44(3):251-3.
Robinson, G. et. al. Novel mutations target distinct subgroups
of medulloblastoma. Nature. 2012 Aug 2;488(7409):43-8.
Schwartzentruber, J. et. al. Driver mutations in histone H3.3
and chromatin remodelling genes in paediatric glioblasto-
ma. Nature. 2012 Jan 29;482(7384):226-31.
Patología en tumores cerebrales
Jiao, Y. et. al. Frequent ATRX, CIC, and FUBP1 mutations refi-
ne the classification of malignant gliomas. Oncotarget. 2012
Jul;3(7):709-22.
Liu, X. Y. et. al. Frequent ATRX mutations and loss of expres-
sion in adult diffuse astrocytic tumors carrying IDH1/IDH2
and TP53 mutations. Acta Neuropathol. 2012 Aug 12.
Lu, K. V. et. al. VEGF inhibits tumor cell invasion and mesen-
chymal transition through a MET/VEGFR2 complex. Cancer
Cell. 2012 Jul 10;22(1):21-35.
Cirugía
Castellano, A. et. al. Role of diffusion tensor magnetic reso-
nance tractography in predicting the extent of resection in
glioma surgery. Neuro Oncol. 2012 Feb;14(2):192-202.
De Witt Hamer, P. C. et. al. Impact of intraoperative stimu-
lation brain mapping on glioma surgery outcome: a meta-
analysis. J Clin Oncol. 2012 Jul 10;30(20):2559-65.
Gans, J. H. et. al. The Role of Radiosurgery to the Tumor Bed
After Resection of Brain Metastases. Neurosurgery. 2012 Nov
30.
Hofmann, B. M. et. al. Results after treatment of craniopharyn-
giomas: further experiences with 73 patients since 1997. J
Neurosurg. 2012 Feb;116(2):373-84.
Radioterapia
Tsien, C. I. et. al. Concurrent temozolomide and dose-esca-
lated intensity-modulated radiation therapy in newly diag-
nosed glioblastoma. Clin Cancer Res. 2012 Jan 1;18(1):273-9.
Pallud, J. et. al. Dynamic imaging response following radia-
tion therapy predicts long-term outcomes for diffuse low-
grade gliomas. Neuro Oncol. 2012 Apr;14(4):496-505.
Metastasis cerebrales
Soffietti, R. et. al. A European Organisation for Research and
Treatment of Cancer Phase III Trial of Adjuvant Whole-Brain
Radiotherapy Versus Observation in Patients With One to
Three Brain Metastases From Solid Tumors After Surgical Re-
section or Radiosurgery: Quality-of-Life Results. J Clin Oncol.
2013 Jan 1;31(1):65-72.

3. 3
RedLANO e–Journal
2 0 1 2
www.redlano.org
( E p u b a h e a d o f p r i n t )
Falchook, G. S. et. al. Dabrafenib in patients with melanoma,
untreated brain metastases, and other solid tumours: a phase
1 dose-escalation trial. Lancet. 2012 May 19;379(9829):1893-
901.
Long, GV. et. al. Dabrafenib in patients with Val600Glu or
Val600Lys BRAF-mutant melanoma metastatic to the brain
(BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet
Oncol. 2012 Nov;13(11):1087-95.
Margolin, K. et. al. Ipilimumab in patients with melanoma
and brain metastases: an open-label, phase 2 trial. Lancet
Oncol. 2012 May;13(5):459-65.
Preusser, M. et. al. Trial design on prophylaxis and treatment
of brain metastases: Lessons learned from the EORTC Bra-
in Metastases Strategic Meeting 2012. Eur J Cancer. 2012
Dec;48(18):3439-47.
Tsao, M. N. et. al. Radiotherapeutic and surgical manage-
ment for newly diagnosed brain metastasis(es): An Ameri-
can Society for Radiation Oncology evidence-based gui-
deline. Practical Radiation Oncology. 2012; 2(3): 210-225.
http://download.journals.elsevierhealth.com/pdfs/jour-
nals/1879-8500/PIIS1879850011003808.pdf
Gliomas de alto grado
Cairncross G, et. al Phase III Trial of Chemoradiotherapy for
Anaplastic Oligodendroglioma: Long-Term Results of RTOG
9402. J Clin Oncol. 2012 Oct 15. [Epub ahead of print]
Van den Bent MJ, et. al. Adjuvant Procarbazine, Lomustine,
and Vincristine Chemotherapy in Newly Diagnosed Ana-
plastic Oligodendroglioma: Long-Term Follow-Up of EORTC
Brain Tumor Group Study 26951. J Clin Oncol. 2012 Oct 15.
[Epub ahead of print]
Malmström A. et. al. Temozolomide versus standard 6-week
radiotherapy versus hypofractionated radiotherapy in pa-
tients older than 60 years with glioblastoma: the Nordic ran-
domised, phase 3 trial. Lancet Oncol. 2012 Sep;13(9):916-26.
Wick, W. et. al. Temozolomide chemotherapy alone versus
radiotherapy alone for malignant astrocytoma in the elderly:
the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012
Jul;13(7):707-15. doi: 10.1016/S1470-2045(12)70164-X. Epub
2012 May 10.
Gliomas de bajo grado
Jakola, A. S. et. al. Comparison of a strategy favoring early
surgical resection vs a strategy favoring watchful waiting in
low-grade gliomas. JAMA. 2012 Nov 14;308(18):1881-8.
Pallud, J. et. al. Quantitative morphological magnetic reso-
nance imaging follow-up of low-grade glioma: a plea for
systematic measurement of growth rates. Neurosurgery.
2012 Sep;71(3):729-39; discussion 739-40.
Potts, M. B. et. al. Natural history and surgical management
of incidentally discovered low-grade gliomas. J Neurosurg.
2012 Feb;116(2):365-72.
Englot, D. J. et. al. Extent of surgical resection predicts seizu-
re freedom in low-grade temporal lobe brain tumors. Neuro-
surgery. 2012 Apr;70(4):921-8.

4. 4
RedLANO e–Journal
2 0 1 2
www.redlano.org
( E p u b a h e a d o f p r i n t )
Linfoma del sistema nervioso central
Ghesquières H, et. al. Evidence of time-dependent prognos-
tic factors predicting early death but not long-term outco-
me in primary CNS lymphoma: a study of 91 patients. Hema-
tol Oncol. 2012 Aug 9.
Gonzalez-Aguilar A, et. al. Recurrent mutations of MYD88
and TBL1XR1 in primary central nervous system lymphomas.
Clin Cancer Res. 2012 Oct 1;18(19):5203-11.
Mappa S, et. al. Salvage chemoimmunotherapy with rituxi-
mab, ifosfamide and etoposide (R-IE regimen) in patients
with primary CNS lymphoma relapsed or refractory to high-
dose methotrexate-based chemotherapy. Hematol Oncol.
2012 Nov 14.
Roth P, et. al. Outcome of elderly patients with primary CNS
lymphoma in the G-PCNSL-SG-1 trial. Neurology. 2012 Aug
28;79(9):890-6.
Welch MR, et. al. Outcomes of the oldest patients with pri-
mary CNS lymphoma treated at Memorial Sloan-Kettering
Cancer Center. Neuro Oncol. 2012 Oct;14(10):1304-11.
Cuidados y soporte paliativo en neuro-oncología
Chochinov, H. M. et. al. The Patient Dignity Inventory:
applications in the oncology setting. J Palliat Med. 2012
Sep;15(9):998-1005.
Colen, C. B. and Allcut, E. Quality of life and outcomes in
glioblastoma management. Neurosurg Clin N Am 23 (2012)
507-513.
Efficace, F. and Taphoorn, M. Methodological issues in de-
signing and reporting health-related quality-of-life in cancer
trials: the challenge of brain cancer studies. J Neurooncolo-
gy (2012) 108: 221-226
Ford, E. et. al. Systematic review of supportive care needs
in patients with primary malignant brain tumours. Neuro-
Oncology 14 (4): 392-404, 2012
Gofton, T. E. et. al. Identifying the palliative care needs of
patients living with cerebral tumours and metastases : a re-
trospective analysis. J Neurooncology (2012) 108: 527-534
de Groot, M. et. al. Epilepsy in patients with a brain tumour:
focal epilepsy requires focused treatment. Brain. 2012
Apr;135 (Pt4):1002-16.
Rooney, A. G. et. al. Frequency, clinical associations, and lon-
gitudinal course of major depressive disorder in adults with
cerebral glioma. J Clin Oncol. 2011 Nov 10;29(32):4307-12.